Clinical Trials Logo

Type2 Diabetes Mellitus clinical trials

View clinical trials related to Type2 Diabetes Mellitus.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03766750 Withdrawn - Clinical trials for Type2 Diabetes Mellitus

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Start date: December 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Lima association in the control of type 2 diabetes mellitus

NCT ID: NCT03675074 Withdrawn - Obesity Clinical Trials

Neujia Anastomosis for Treatment of Obesity and Type II Diabetes

NEUJIA 1A
Start date: September 12, 2018
Phase: N/A
Study type: Interventional

This prospective, multicenter, open label, single arm study will enroll subjects presenting with obesity and inadequately controlled type II diabetes (T2DM). A dual path jejunoileal side-to-side anastomosis is endoscopically created using the Neujia device. Subjects are followed for 12 months and annually thereafter for up to 5 years to assess change in metabolic parameters, medications, weight, and adverse events.

NCT ID: NCT03190798 Withdrawn - Clinical trials for Cardiovascular Diseases

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Start date: September 1, 2017
Phase: Phase 4
Study type: Interventional

RESEARCH HYPOTHESIS - In subjects with T2DM and HF, effect of canagliflozin will be superior to placebo for the change from baseline in PCWP after a single dose (6 hours post-dose) and after 4 weeks. - Treatment with canagliflozin will be well tolerated over 4 weeks.

NCT ID: NCT03008395 Withdrawn - Clinical trials for Type2 Diabetes Mellitus

Empowerment, Motivation and Medical Adherence (EMMA).

EMMA
Start date: October 2017
Phase: N/A
Study type: Interventional

Outcomes in type 2 diabetes are largely achieved by self-management efforts by individuals living with diabetes. Diabetes self-management is typically provided using the principles of adult education. Current evidence suggests that standard educational interventions are suboptimal. This study evaluates a novel approach to diabetes self-management using dialogue tools based on empowerment and motivational communication methods. The approach evaluated in this study is called EMMA: empowerment, motivation and medical adherence. Participants will be randomized to EMMA and treatment as usual, treated for a period of 4 months and evaluated over a period of 12 months.